Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial

Authors

Sube Banerjee
Juliet High, University of East Anglia
Susan Stirling, University of East Anglia
Lee Shepstone, University of East Anglia
Ann Marie Swart, University of East Anglia
Tanya Telling, University of Sussex
Catherine Henderson, The London School of Economics and Political Science
Clive Ballard, University of Exeter
Peter Bentham, Birmingham and Solihull Mental Health NHS Foundation Trust
Alistair Burns, University of Manchester
Nicolas Farina, Peninsula Medical School
Chris Fox, University of East Anglia
Paul Francis, University of Exeter
Robert Howard, University College London
Martin Knapp, The London School of Economics and Political Science
Iracema Leroi, Trinity College Dublin
Gill Livingston, University College London
Ramin Nilforooshan, Surrey and Borders Partnership NHS Foundation Trust
Shirley Nurock, University of Cambridge
John O'Brien, University of Cambridge
Annabel Price, Cambridgeshire and Peterborough NHS Foundation Trust
Alan J. Thomas, Newcastle University
Naji Tabet, University of Sussex

ORCID

• Sube Banerjee: 0000-0002-8083-7649
• Nicolas Farina: 0000-0002-0635-2547

DOI

10.1016/s0140-6736(21)01210-1

Publication Date

2021-10-21

Publication Title

The Lancet

Volume

398

Issue

10310

ISSN

0140-6736

Embargo Period

2022-03-08

First Page

1487

Last Page

1497

Recommended Citation

Banerjee, S., High, J., Stirling, S., Shepstone, L., Swart, A., Telling, T., Henderson, C., Ballard, C., Bentham, P., Burns, A., Farina, N., Fox, C., Francis, P., Howard, R., Knapp, M., Leroi, I., Livingston, G., Nilforooshan, R., Nurock, S., O'Brien, J., Price, A., Thomas, A., & Tabet, N. (2021) 'Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial', The Lancet, 398(10310), pp. 1487-1497. Available at: 10.1016/s0140-6736(21)01210-1